KR900009089A - 알카토닌 수용액 조성물 - Google Patents

알카토닌 수용액 조성물 Download PDF

Info

Publication number
KR900009089A
KR900009089A KR1019890016984A KR890016984A KR900009089A KR 900009089 A KR900009089 A KR 900009089A KR 1019890016984 A KR1019890016984 A KR 1019890016984A KR 890016984 A KR890016984 A KR 890016984A KR 900009089 A KR900009089 A KR 900009089A
Authority
KR
South Korea
Prior art keywords
elkatonin
aqueous solution
compound
composition
monocarboxy
Prior art date
Application number
KR1019890016984A
Other languages
English (en)
Other versions
KR950003493B1 (ko
Inventor
히도시 야마다
켄 엔도오
기꾸오 고다니
Original Assignee
다까다 데쓰오
도오요오 죠조오 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다까다 데쓰오, 도오요오 죠조오 가부시기가이샤 filed Critical 다까다 데쓰오
Publication of KR900009089A publication Critical patent/KR900009089A/ko
Application granted granted Critical
Publication of KR950003493B1 publication Critical patent/KR950003493B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음.

Description

알카토닌 수용액 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 유효성분으로서 엘카토닌 유효량과 몰농도가 0.05 내지 20mmol인 모노카르복시화합물 또는 수용성염으로 이루어진 군으로부터 선택된 하나이상의 화합물을 함유하고 pH가 5.0 내지 6.5이고 이온강도가 μ=0.01 내지 0.5인 것을 특징으로 하는 엘카토닌 수용액조성물.
  2. 제1항에 있어서, 모노카르복시화합물이 초산인 것을 특징으로 하는 엘카토닌수용액조성물.
  3. 제1항에 있어서, 모노카르복시화합물이 유산인 것을 특징으로 하는 엘카토닌수용액조성물.
  4. 제1항에 있어서, 모노카라복시화합물이 L-히스티딘인 것을 특징으로 하는 엘카토닌수용액 조성물.
  5. 제1항에 있어서, 카르복시화합물이 염이 초산나트륨, 초산칼륨, 유산나트륨, 유산칼륨, 또는 L-히스티딘 염산염인 것을 특징으로 하는 엘카토닌수용액조성물.
  6. 제1항에 있어서, 엘카토닌함량이 용액 1ml당 1 내지 100㎍인 것을 특징으로 하는 엘카토닌수용액조성물.
  7. 몰농도가 0.05 내지 20mmol인 모노카르복시화합물과 그것의 염으로 이루어진 군으로부터 선택된 하나이상의 화합물을 함유하고, 5,0 내지 6.5의 pH와 μ=0.01-0.5의 이온강도를 가진 수성매체에 유효량의 엘카토닌을 용해하는 것으로 이루어지는 것을 특징으로 하는 엘카토닌수용액조성물의 제조공정.
  8. 제1항에 있어서, 엘카토닌수용액조성물을 합유하는 것을 특징으로 하는 주사제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890016984A 1988-12-23 1989-11-22 알카토닌 수용액조성물 KR950003493B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP63-324999 1988-12-23
JP???63-324999 1988-12-23
JP63324999A JPH02174726A (ja) 1988-12-23 1988-12-23 エルカトニン水溶液組成物の安定化法

Publications (2)

Publication Number Publication Date
KR900009089A true KR900009089A (ko) 1990-07-02
KR950003493B1 KR950003493B1 (ko) 1995-04-13

Family

ID=18172004

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890016984A KR950003493B1 (ko) 1988-12-23 1989-11-22 알카토닌 수용액조성물

Country Status (10)

Country Link
US (1) US4977139A (ko)
EP (1) EP0375885B1 (ko)
JP (1) JPH02174726A (ko)
KR (1) KR950003493B1 (ko)
AT (1) ATE83380T1 (ko)
AU (1) AU629142B2 (ko)
CA (1) CA2001671C (ko)
DE (1) DE68903937T2 (ko)
ES (1) ES2052861T3 (ko)
GR (1) GR3007338T3 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
US5721207A (en) * 1995-04-18 1998-02-24 Innapharma, Inc. Method for treatment of pain
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
JP2002037737A (ja) * 2001-08-02 2002-02-06 Nippon Kayaku Co Ltd ブレオマイシン類の安定な水溶液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51128993A (en) * 1975-05-01 1976-11-10 Tanpakushitsu Kenkyu Shiyoureikai Process for preparing new polypeptides
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤

Also Published As

Publication number Publication date
EP0375885B1 (en) 1992-12-16
DE68903937D1 (de) 1993-01-28
US4977139A (en) 1990-12-11
AU629142B2 (en) 1992-09-24
EP0375885A1 (en) 1990-07-04
JPH0524137B2 (ko) 1993-04-06
ES2052861T3 (es) 1994-07-16
JPH02174726A (ja) 1990-07-06
AU4397589A (en) 1990-06-28
CA2001671A1 (en) 1990-06-23
KR950003493B1 (ko) 1995-04-13
DE68903937T2 (de) 1993-04-22
GR3007338T3 (ko) 1993-07-30
ATE83380T1 (de) 1993-01-15
CA2001671C (en) 1995-10-17

Similar Documents

Publication Publication Date Title
DE3871434D1 (de) Stabilisierte wasserstoffperoxidloesung.
ES2014309T5 (es) Utilizacion de una sal para influenciar el vertido de composiciones espesas.
KR840007596A (ko) 유기인 유도체의염의 제조방법
DK483587D0 (da) Antiperspirant praeparat
DE69111205T2 (de) Stabilisierung von Calcitonin enthaltenden pharmazeutischen Verbindungen.
KR880007059A (ko) 염화리소짐 및 글리치르히진산 디칼륨 함유 수용액 제제
RU97113465A (ru) Инъекционные или инфузионные растворы энрофлоксацина
KR900009089A (ko) 알카토닌 수용액 조성물
ATE65083T1 (de) Verfahren zur herstellung von benzothiazepinderivaten.
ATE178884T1 (de) Salze von 2-((2,6- dichlorophenyl)amin>phenylacetoxyessigsäure mit organischen basischen kationen
JP3262592B2 (ja) 〔Ａｓｕ１．７〕カルシトニン類の水溶液注射剤の安定化法
ATE192749T1 (de) Wässrige spectinomycinborat-auflösung
PT79821B (fr) Procede de preparation d'aminoethylimidazole comme de la composition pharmaceutique en contenant utilise comme medicament cytoprotecteur
KR890006663A (ko) 칼슘 5'-리보누클레오티드의 제조방법
KR920014774A (ko) 페녹시알킬카복실산 유도체 및 이의 제조방법
KR900006271A (ko) S-디플루오로메틸호도시스테인, 제조방법 및 그를 함유하는 선택적인 살충제
KR880011077A (ko) 유효치료 물질로서 사용하기 위한 tert- 부틸아미노-3(페닐-2'-펜옥시)-1-프로판올-2 및 그의 산부가염
KR860004074A (ko) N-포스포노 메틸 글리신 염의 제조방법
UA43797A (uk) Ін'єкційна форма препарату, що проявляє протиішемічну активність

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090410

Year of fee payment: 15

EXPY Expiration of term